Publication Date
| In 2025 | 0 |
| Since 2024 | 0 |
| Since 2021 (last 5 years) | 1 |
| Since 2016 (last 10 years) | 3 |
| Since 2006 (last 20 years) | 8 |
Descriptor
| Drug Therapy | 8 |
| Hyperactivity | 8 |
| Behavior Problems | 6 |
| Children | 6 |
| Autism | 5 |
| Outcomes of Treatment | 4 |
| Pervasive Developmental… | 4 |
| Symptoms (Individual… | 4 |
| Check Lists | 3 |
| Adolescents | 2 |
| Attention Deficit Disorders | 2 |
| More ▼ | |
Source
| Autism: The International… | 2 |
| Autism: The International… | 1 |
| Journal of Autism and… | 1 |
| Journal of Intellectual &… | 1 |
| Journal of the American… | 1 |
| Journal of the American… | 1 |
| Research in Developmental… | 1 |
Author
| Aman, Michael G. | 3 |
| Arnold, L. Eugene | 3 |
| Bearss, Karen | 1 |
| Berk, Michael | 1 |
| Bernier, Raphael A. | 1 |
| Bodfish, James | 1 |
| Brown, Ellie | 1 |
| Byrne, Linda K. | 1 |
| Chawarska, Katarzyna | 1 |
| Cook, Amelia M. | 1 |
| Dawson, Geraldine | 1 |
| More ▼ | |
Publication Type
| Journal Articles | 8 |
| Reports - Research | 7 |
| Reports - Evaluative | 1 |
Education Level
Audience
Location
| North Carolina | 2 |
| Australia | 1 |
| California (Los Angeles) | 1 |
| Connecticut (New Haven) | 1 |
| Illinois (Chicago) | 1 |
| Massachusetts (Boston) | 1 |
| Michigan | 1 |
| Washington | 1 |
Laws, Policies, & Programs
Assessments and Surveys
| Aberrant Behavior Checklist | 8 |
| Autism Diagnostic Observation… | 1 |
| Beck Depression Inventory | 1 |
| Developmental Behavior… | 1 |
| Social Responsiveness Scale | 1 |
| Vineland Adaptive Behavior… | 1 |
What Works Clearinghouse Rating
Peer reviewed
Direct linkShurtz, Logan; Schwartz, Chloe; DiStefano, Charlotte; McPartland, James C.; Levin, April R.; Dawson, Geraldine; Kleinhans, Natalia M.; Faja, Susan; Webb, Sara J.; Shic, Frederick; Naples, Adam J.; Seow, Helen; Bernier, Raphael A.; Chawarska, Katarzyna; Sugar, Catherine A.; Dziura, James; Senturk, Damla; Santhosh, Megha; Jeste, Shafali S. – Autism: The International Journal of Research and Practice, 2023
Children with autism spectrum disorder are prescribed various medications to address behavior and mood. In clinical trials, individuals taking concomitant psychotropic medications often are excluded to maintain homogeneity and prevent contamination of clinical endpoints. However, this choice may compromise the representativeness of the sample. In…
Descriptors: Autism Spectrum Disorders, Drug Therapy, Incidence, Child Behavior
Dean, Olivia M.; Gray, Kylie; Dodd, Seetal; Villagonzalo, Kristi-Ann; Brown, Ellie; Tonge, Bruce; Berk, Michael; Byrne, Linda K. – Journal of Intellectual & Developmental Disability, 2019
Background: Traditional treatment for the behavioural symptoms in autism spectrum disorder (ASD) remains unsatisfactory. There is an urgent need for new, biologically relevant therapies that target both the core and comorbid symptoms that children may experience. This article builds on research previously published by the authors. Method: We…
Descriptors: Autism, Pervasive Developmental Disorders, Intervention, Children
Lord, Catherine; McCauley, James B.; Pepa, Lauren A.; Huerta, Marisela; Pickles, Andrew – Autism: The International Journal of Research and Practice, 2020
Longitudinal data on the functioning of adults referred for possible autism as children are sparse and possibly different from datasets consisting of adult clinical referrals. A total of 123 young adults, mean age of 26, referred for neurodevelopmental disorders in early childhood were categorized into three outcome groups: autism spectrum…
Descriptors: Autism, Pervasive Developmental Disorders, Young Adults, Intelligence Quotient
Farmer, Cristan; Lecavalier, Luc; Yu, Sunkyung; Arnold, L. Eugene; McDougle, Christopher J.; Scahill, Lawrence; Handen, Benjamin; Johnson, Cynthia R.; Stigler, Kimberly A.; Bearss, Karen; Swiezy, Naomi B.; Aman, Michael G. – Journal of Autism and Developmental Disorders, 2012
The Research Units on Pediatric Psychopharmacology-Autism Network reported additional benefit when adding parent training (PT) to antipsychotic medication in children with autism spectrum disorders and serious behavior problems. The intent-to-treat analyses were rerun with putative predictors and moderators. The "Home Situations…
Descriptors: Behavior Problems, Autism, Hyperactivity, Predictor Variables
Aman, Michael G.; Hollway, Jill A.; Leone, Sarah; Masty, Jessica; Lindsay, Ronald; Nash, Patricia; Arnold, L. Eugene – Research in Developmental Disabilities: A Multidisciplinary Journal, 2009
This study was designed to explore the placebo-controlled effects of risperidone on cognitive-motor processes, dyskinetic movements, and behavior in children receiving maintenance risperidone therapy. Sixteen children aged 4-14 years with disruptive behavior were randomly assigned to drug order in a crossover study of risperidone and placebo for 2…
Descriptors: Metabolism, Behavior Problems, Reaction Time, Hyperactivity
Woodard, Cooper; Groden, June; Goodwin, Matthew; Bodfish, James – Autism: The International Journal of Research & Practice, 2007
We used a mixed group/single-case, double-blind, placebo-controlled, ABAB design to examine the safety and efficacy of the glutamate antagonist dextromethorphan for the treatment of problematic behaviors and core symptoms in eight children diagnosed with autism. All participants had increased levels of irritability at baseline as measured by the…
Descriptors: Drug Therapy, Behavior Problems, Symptoms (Individual Disorders), Children
Atomoxetine for Hyperactivity in Autism Spectrum Disorders: Placebo-Controlled Crossover Pilot Trial
Arnold, L. Eugene; Aman, Michael G.; Cook, Amelia M.; Witwer, Andrea N.; Hall, Kristy L.; Thompson, Susan; Ramadan, Yaser – Journal of the American Academy of Child and Adolescent Psychiatry, 2006
Objective: To explore placebo-controlled efficacy and safety of atomoxetine (ATX) for attention-deficit/hyperactivity disorder (ADHD) symptoms in children with autism spectrum disorders (ASD). Method: Children ages 5 to 15 with ASD and prominent ADHD symptoms were randomly assigned to order in a crossover of clinically titrated ATX and placebo, 6…
Descriptors: Hyperactivity, Autism, Drug Therapy, Attention Deficit Disorders
Handen, Benjamin L.; Hardan, Antonio Y. – Journal of the American Academy of Child & Adolescent Psychiatry, 2006
Objective: Olanzapine, an atypical antipsychotic, has been shown to be efficacious for treatment of psychotic and mood disorders in adults. This prospective, open-label study was conducted to examine the safety and usefulness of olanzapine in treating disruptive behavior disorders in adolescents with subaverage intelligence. Method: Sixteen…
Descriptors: Check Lists, Intelligence, Safety, Moderate Mental Retardation
